Rapidemic

Netherlands
Leiden, South Holland, The Netherlands, 2312

Company profile

Rapidemic company profile

Rapidemic develops a molecular point-of-care test for the diagnosis of sexually transmitted infections. Their proprietary technology increases the sensitivity and specificity of the reaction while keeping manipulations to a minimum. Its technology enables low-temperature diagnostics while safeguarding accuracy and reducing false positives.

Business identity

Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2020-01-01, Year

Headquarters

Postal code
2312
Country code
NL
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Seed
Funding rounds
4
Total equity funding
$165,087
Last funding
Grant / $3.1M / 2025-09-25
Last equity funding
Pre Seed / $80,446
Investors
3
Lead investors
2
Articles
6

Founders and investors

Lead investors

Bill & Melinda Gates FoundationBioInnovation Institute

Investors

Bill & Melinda Gates FoundationBioInnovation InstituteGraduate Ventures